title: Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis.
authors.affiliation: Department of Neurology, 'F. Tappeiner' Hospital Merano, Via Rossini, 5, 39012 Merano (BZ), Italy. raffaele.nardone@asbmeran-o.it.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Nardone
authors.forename: Giulio
authors.initials: G
authors.lastname: Zuccoli
authors.forename: Francesco
authors.initials: F
authors.lastname: Brigo
authors.forename: Eugen
authors.initials: E
authors.lastname: Trinka
authors.forename: Stefan
authors.initials: S
authors.lastname: Golaszewski
mesh_terms: D000068879:Adalimumab; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001706:Biopsy; D001921:Brain / Q000469:parasitology / Q000473:pathology; D006801:Humans; D008297:Male; D012307:Risk Factors; D014122:Toxoplasma / Q000302:isolation & purification; D016781:Toxoplasmosis, Cerebral / Q000139:chemically induced / Q000175:diagnosis / Q000209:etiology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab